Inhibikase Therapeutics Inc (IKT) — Cash Flow Reinvestment Rate
Inhibikase Therapeutics Inc (IKT) has a Cash Flow Reinvestment Rate of 0.00x as of September 2020, reinvesting $0.00 (capex $0.00 ) from operating cash flow of $75.52K. See Inhibikase Therapeutics Inc (IKT) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Inhibikase Therapeutics Inc Cash Flow Reinvestment Rate (2018–2018)
Historical reinvestment intensity for Inhibikase Therapeutics Inc across 1 annual periods. For the full cash flow conversion analysis, see IKT cash flow metrics.
Annual Cash Flow Reinvestment Rate for Inhibikase Therapeutics Inc (2018–2018)
Year-by-year capital reinvestment analysis for Inhibikase Therapeutics Inc. See IKT financial flexibility index to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2018 | 0.12x | $87.10K | $714.99K | $0.00 | — |